<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7093024/results/search/disease/results.xml">
  <result pre="Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza" exact="Viral" post="Neuraminidase Inhibitors LiPing1†DuRuikun123†WangYanyan1HouXuewen1WangLin1ZhaoXiujuan1ZhanPeng4LiuXinyong4RongLijun5*CuiQinghua123*[], 1College of Pharmacy, Shandong University of"/>
  <result pre="identified as novel inhibitors against IAV replication. A reporter virus-based" exact="infection" post="assay demonstrated that CHLA and CHLI exhibit no inhibitory"/>
  <result pre="or RNA replication during the virus replication cycle. Results of" exact="viral" post="release inhibition assay and neuraminidase (NA) inhibition assay indicated"/>
  <result pre="CHLA and CHLI exert their inhibitory effect on the NA-mediated" exact="viral" post="release. Moreover, oseltamivir-resistance mutation NA/H274Y of NA is susceptible"/>
  <result pre="Introduction Influenza vaccines and antiviral drugs are effective in preventing" exact="infection" post="or ameliorating disease severity (Vasileiou et al., 2017). However,"/>
  <result pre="and antiviral drugs are effective in preventing infection or ameliorating" exact="disease" post="severity (Vasileiou et al., 2017). However, influenza infection, as"/>
  <result pre="severity (Vasileiou et al., 2017). However, influenza infection, as an" exact="acute" post="respiratory disease caused by seasonal outbreaks and, periodically, pandemics"/>
  <result pre="(Vasileiou et al., 2017). However, influenza infection, as an acute" exact="respiratory" post="disease caused by seasonal outbreaks and, periodically, pandemics of"/>
  <result pre="et al., 2017). However, influenza infection, as an acute respiratory" exact="disease" post="caused by seasonal outbreaks and, periodically, pandemics of influenza"/>
  <result pre="available classes of antivirals for treatment and prevention of influenza" exact="infections" post="are the viral ion channel M2 blockers (amantadine and"/>
  <result pre="antivirals for treatment and prevention of influenza infections are the" exact="viral" post="ion channel M2 blockers (amantadine and rimantadine), neuraminidase (NA)"/>
  <result pre="until use. Cells, Viruses, and Compounds Madin–Darby canine kidney (MDCK)" exact="epithelial" post="cells were grown in Dulbecco’s modified Eagle’s medium (DMEM;"/>
  <result pre="and 100 μg/mL of streptomycin (Invitrogen, Carlsbad, CA, United States)." exact="Infections" post="were performed in Opti-MEM containing 2 μg/mL N-tosyl- L-phenylalanine"/>
  <result pre="with recombinant reporter virus PR8-PB2-Gluc at an MOI of 0.01." exact="Infection" post="was quantified after 36 h of incubation by measuring"/>
  <result pre="at 25 μg/mL in 0.125% DMSO (v/v) to confirm the" exact="primary" post="results. Cell cytotoxicity was examined 48 h post-treatment using"/>
  <result pre="Prism software (version 5.02, La Jolla, CA, United States). One-Cycle" exact="Infection" post="Inhibition Assay To determine whether the hit natural product"/>
  <result pre="hit natural product samples or its derivatives were target to" exact="viral" post="entry or genome replication steps, a one-cycle infection inhibition"/>
  <result pre="target to viral entry or genome replication steps, a one-cycle" exact="infection" post="inhibition assay was carried out using the reporter virus"/>
  <result pre="of Opti-MEM containing 2 μg/mL of TPCK–trypsin, was used during" exact="infection" post="to avoid HA cleavage and infectious virus production. After"/>
  <result pre="TPCK–trypsin, was used during infection to avoid HA cleavage and" exact="infectious" post="virus production. After 24 h, infections were quantified by"/>
  <result pre="avoid HA cleavage and infectious virus production. After 24 h," exact="infections" post="were quantified by measuring the luciferase activity with PierceTM"/>
  <result pre="decrease in fluorescence was monitored to reflect NA inhibition efficacy." exact="Viral" post="Yield Reduction Assay Viral yield reduction assay was performed"/>
  <result pre="monitored to reflect NA inhibition efficacy. Viral Yield Reduction Assay" exact="Viral" post="yield reduction assay was performed as previously described (Zhu"/>
  <result pre="influenza A PR8-PB2-Gluc virus (Zhao et al., 2019) in a" exact="primary" post="screen and confirmation screen. As a result, 12 hit"/>
  <result pre="a result, 12 hit samples were identified to inhibit IAV" exact="infection" post="(Supplementary Table S1). Among the most potent anti-IAV natural"/>
  <result pre="and chebulinic acid (CHLI) as novel antiviral actives against influenza" exact="virus infection." post="(A) Antiviral determination of 15 overlapped components of unripe"/>
  <result pre="CHLA and CHLI on IAV replication, a reporter IAV-based one-cycle" exact="infection" post="assay was performed. Briefly, MDCK cells were infected by"/>
  <result pre="IAV entry or RNA replication. FIGURE 3 Reporter luciferase-based one-cycle" exact="infection" post="inhibition assay. MDCK cells growing in 96-well plates were"/>
  <result pre="fetal bovine serum (FBS) were used as culture medium during" exact="infection" post="to avoid generation of infectious progeny viruses. At 24"/>
  <result pre="used as culture medium during infection to avoid generation of" exact="infectious" post="progeny viruses. At 24 h post infection (p.i.), Gluc"/>
  <result pre="avoid generation of infectious progeny viruses. At 24 h post" exact="infection" post="(p.i.), Gluc expression was determined, and viral infectivities were"/>
  <result pre="24 h post infection (p.i.), Gluc expression was determined, and" exact="viral" post="infectivities were evaluated. Data are means ± SD from"/>
  <result pre="0.01; Student’s t-test. CHLA and CHLI Target NA to Block" exact="Viral" post="Release The effects of CHLA and CHLI on viral"/>
  <result pre="Block Viral Release The effects of CHLA and CHLI on" exact="viral" post="release were next investigated by a viral release inhibition"/>
  <result pre="and CHLI on viral release were next investigated by a" exact="viral" post="release inhibition assay. Briefly, infected cells were washed and"/>
  <result pre="assay. Briefly, infected cells were washed and cultured in an" exact="infection" post="medium for another 2 h, in the absence or"/>
  <result pre="Student’s t-test. It has been well documented that the influenza" exact="viral" post="NA activity contributes to progeny virus release from an"/>
  <result pre="al., 2019). We therefore examined whether CHLA and CHLI blocked" exact="viral" post="release of IAV by inhibiting viral NA activity. A"/>
  <result pre="CHLA and CHLI blocked viral release of IAV by inhibiting" exact="viral" post="NA activity. A standard fluorimetric method was used (Li"/>
  <result pre="and the results showed that both CHLA and CHLI inhibited" exact="viral" post="NA activity in a dose-dependent manner (Figure 4B). Together,"/>
  <result pre="that CHLA and CHLI inhibit IAV replication by preventing the" exact="viral" post="NA-mediated progeny virus release. CHLA and CHLI Are Effective"/>
  <result pre="CHLA (1.26 μM) and CHLI (1.58 μM) upon A/H1N1/PR8 were" exact="lower" post="than that of oseltamivir carboxylate (3.92 μM), suggesting their"/>
  <result pre="that CHLA and CHLI exhibit broad-spectrum antiviral activities by targeting" exact="viral" post="glycoprotein–glycosaminoglycan interactions (Lin et al., 2011, 2013; Kesharwani et"/>
  <result pre="due to the more favorable structure for entering the binding" exact="cavities" post="or catalytic pockets of target proteases or enzymes. However,"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="(2016). Peramivir: a novel intravenous neuraminidase inhibitor for treatment of" exact="acute" post="influenza infections.Front. Microbiol.7:450. 10.3389/fmicb.2016.0045027065996 Alves GalvaoM. G.Rocha Crispino SantosM."/>
  <result pre="S.LindstromW. M.Jr.OlsonA. J.LinJ. H.et al. (2007). Remarkable loop flexibility in" exact="avian influenza" post="N1 and its implications for antiviral drug design.J. Am."/>
  <result pre="B.McCormickC.et al. (2011). Hydrolyzable tannins (chebulagic acid and punicalagin) target" exact="viral" post="glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry"/>
  <result pre="(chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit" exact="herpes" post="simplex virus 1 entry and cell-to-cell spread.J. Virol.854386–4398. 10.1128/jvi.01492-1021307190"/>
  <result pre="J.CollinsP. J.LinY. P.BlackburnG. M.et al. (2006). The structure of H5N1" exact="avian influenza" post="neuraminidase suggests new opportunities for drug design.Nature44345–49. 10.1038/nature0511416915235 SamsonM.PizzornoA.AbedY.BoivinG."/>
  <result pre="Chem.4056563–6572. 10.1007/s00216-013-7068-x23748498 TakashitaE.KawakamiC.OgawaR.MoritaH.FujisakiS.ShirakuraM.et al. (2019). Influenza A(H3N2) virus exhibiting reduced" exact="susceptibility to" post="baloxavir due to a polymerase acidic subunit I38T substitution"/>
  <result pre="of influenza A virus (H1N1) fusion by benzenesulfonamide derivatives targeting" exact="viral" post="hemagglutinin.PLoS One. 6:e29120. 10.1371/journal.pone.002912022195002 ZuM.LiC.FangJ. S.LianW. W.LiuA. L.ZhengL. S.et"/>
 </snippets>
</snippetsTree>
